CEVA/Biomune

VECTORMUNE® HVT IBD and VECTORMUNE® HVT NDV are the two latest recombinant vaccines licensed by CEVA BIOMUNE, a member of the CEVA Group. CEVA BIOMUNE is a leader in the research, development, licensing and production of an extended line of live, inactivated, recombinant and customized vaccines for the poultry industry. VECTORMUNE HVT IBD and VECTORMUNE HVT NDV are the 8th and 9th licenses for vectored poultry vaccines granted to Biomune by the USDA. The VECTORMUNE HVT line using the turkey herpesvirus (HVT) as a vector joins the very successful VECTORMUNE FP line of poultry vaccines that use the fowl poxvirus as a vector.